Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log in to HL Account

NGM Biopharmaceuticals Inc (NGM) USD0.001

Sell:$16.34 Buy:$16.39 Change: $0.1 (0.61%)
NASDAQ:0.33%
Market closed |  Prices as at close on 20 October 2020 | Switch to live prices |
Sell:$16.34
Buy:$16.39
Change: $0.1 (0.61%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 October 2020 | Switch to live prices |
Sell:$16.34
Buy:$16.39
Change: $0.1 (0.61%)
Market closed |  Prices as at close on 20 October 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The Company’s product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer.

Contact details

Address:
333 Oyster Point Blvd
SOUTH SAN FRANCISCO
94080-1978
United States
Telephone:
+1 (650) 2435555
Website:
https://www.ngmbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NGM
ISIN:
US62921N1054
Market cap:
$1.14 billion
Shares in issue:
68.83 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • William Rieflin
    Executive Chairman of the Board of Directors
  • David Woodhouse
    Chief Executive Officer, Director
  • Jin-Long Chen
    Founder, Chief Scientific Officer, Director
  • Siobhan Mangini
    Chief Financial Officer
  • Valerie Pierce
    Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
  • Alex DePaoli
    Senior Vice President, Chief Translational Officer
  • Hsiao Lieu
    Senior Vice President, Chief Medical Officer
  • Wenyan Shen
    Senior Vice President - Biologics and CMC
  • Hui Tian
    Senior Vice President - Research
  • Marc Learned
    Vice President - Research Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.